Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Clin Pathol. 2013 Sep;140(3):329-40. doi: 10.1309/AJCP66AVBANVNTQJ.

Clinicopathologic significance of combined hepatocellular-cholangiocarcinoma with stem cell subtype components with reference to the expression of putative stem cell markers.

Author information

1
Section of Diagnostic Pathology, Kanazawa University Hospital, Kanazawa 920-8641, Japan. h-ikeda@med.kanazawa-u.ac.jp

Abstract

OBJECTIVES:

To examine the clinicopathologic features of combined hepatocellular-cholangiocarcinoma (HC-CC), which the World Health Organization (WHO) proposed classifying into 2 types, and the expression of delta-like 1 homolog (DLK1), as well as putative stem cell markers, such as NCAM/CD56 and CD133.

METHODS:

In this study we examined the expression of stem cell markers using immunohistochemistry.

RESULTS:

Thirty-six cases of combined HC-CC were subclassified into 24 cases, with more than 5% stem cell features (group B) and 12 cases with less than 5% stem cell areas (group A). The postoperative overall survival rate was worse for group B than for group A. DLK1 was frequently expressed in group B cases compared with group A, hepatocellular carcinoma, and intrahepatic cholangiocarcinoma cases.

CONCLUSIONS:

The 2010 WHO classification seems important for elucidating the pathogenesis of stem cell-related liver cancers.

KEYWORDS:

Combined hepatocellular-cholangiocarcinoma; DLK1; Hepatoblast; NCAM/CD56; Stem cells

PMID:
23955451
DOI:
10.1309/AJCP66AVBANVNTQJ
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center